Susan Galbraith
Impact in
- Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
Papers in
-
- Cancer, Hypoxia, and Metabolism 6
- Protease and Inhibitor Mechanisms 5
- Oncology 19
- Cancer Treatment and Pharmacology 7
- Co-authors
- Gordon RustinN. Jane TaylorAnwar R. PadhaniMartin A. LodgeJames StirlingGillian M. TozerLindsey GumbrellMichael R.L. Stratford
- Journals
- Journal of Clinical Oncology (18 papers)Molecular Cancer Therapeutics (2 papers)British Journal of Cancer (2 papers)NMR in Biomedicine (2 papers)Cancer Discovery (2 papers)
- Partner nations
- United StatesUnited KingdomNetherlands
In The Last Decade
Susan Galbraith
44 papers receiving 2.8k citations
Peers
Comparison fields: 5 of 106
- Cancer Research 610
- Oncology 1.1k
- Radiology, Nuclear Medicine and Imaging 696
- Hepatology 147
- Hematology 197
Countries citing papers authored by Susan Galbraith
This map shows the geographic impact of Susan Galbraith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Galbraith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Galbraith more than expected).
Fields of papers citing papers by Susan Galbraith
This network shows the impact of papers produced by Susan Galbraith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Galbraith. The network helps show where Susan Galbraith may publish in the future.
Co-authors
The 25 scholars most cited alongside Susan Galbraith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 0 | |
| 3 | 2023 | 11 | |
| 4 | 2023 | 8 | |
| 5 | 2021 | 17 | |
| 6 | 2011 | 23 | |
| 7 | 2010 | 61 | |
| 8 | 2009 | 14 | |
| 9 | 2009 | 116 | |
| 10 | 2008 | 158 | |
| 11 | 2007 | 31 | |
| 12 | 2006 | 18 | |
| 13 | Preclinical studies of BMS-582664, an alanine prodrug of BMS-540215, a potent, dual inhibitor of VEGFR-2 and FGFR-1 kinases | 2005 | 1 |
| 14 | 2004 | 2 | |
| 15 | 2003 | 100 | |
| 16 | 2003 | 15 | |
| 17 | ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. | 2002 | 200 |
| 18 | 2002 | 278 | |
| 19 | 2002 | 121 | |
| 20 | 1996 | 90 |
About Susan Galbraith
Susan Galbraith is a scholar working on Cancer Research, Oncology, Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Hematology, having authored 45 papers that have together received 2.9k indexed citations. Recurring topics across this work include MRI in cancer diagnosis (8 papers), Cancer Treatment and Pharmacology (7 papers), Radiomics and Machine Learning in Medical Imaging (7 papers), Cancer, Hypoxia, and Metabolism (6 papers), Angiogenesis and VEGF in Cancer (6 papers), Lung Cancer Treatments and Mutations (6 papers), Fibroblast Growth Factor Research (5 papers) and Protease and Inhibitor Mechanisms (5 papers). The work is most often cited by research in Cancer Research (610 citations), Oncology (1.1k citations), Radiology, Nuclear Medicine and Imaging (696 citations), Hepatology (147 citations) and Hematology (197 citations). Susan Galbraith has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Gordon Rustin, N. Jane Taylor, Anwar R. Padhani, Martin A. Lodge, James Stirling, Gillian M. Tozer, Lindsey Gumbrell, Michael R.L. Stratford, Lisa K. Folkes and David M. Berman. Their work appears in journals such as Journal of Clinical Oncology, Molecular Cancer Therapeutics, British Journal of Cancer, NMR in Biomedicine and Cancer Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.